Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCEP.123.011681 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Self-Administered Etripamil Nasal Spray Relieved Symptoms, Decreased Heart Rate, and Reduced Medical Interventions During Atrioventricular Nodal-Dependent Paroxysmal Supraventricular Tachycardia.
Circ Arrhythm Electrophysiol
December 2024
Clinical Cardiology, St. George's University of London, London, United Kingdom (A.J.C.).
Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings.
Am Heart J
April 2024
Piedmont Healthcare, Atlanta, GA.
Background: Paroxysmal supraventricular tachycardia (PSVT) is a common episodic arrhythmia characterized by unpredictable onset and burdensome symptoms including palpitations, dizziness, chest pain, distress, and shortness of breath. Treatment of acute episodes of PSVT in the clinical setting consists of intravenous adenosine, beta-blockers, and calcium channel blockers (CCBs). Etripamil is an intranasally self-administered L-type CCB in development for acute treatment of AV-nodal dependent PSVT in a nonmedical supervised setting.
View Article and Find Full Text PDFMulticenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201).
Circ Arrhythm Electrophysiol
December 2023
Department of Medicine, Montreal Heart Institute, Québec, Canada (G.G., M.-C.G., B.M., D.R.).
Background: Despite chronic therapies, atrial fibrillation (AF) leads to rapid ventricular rates (RVR) often requiring intravenous treatments. Etripamil is a fast-acting, calcium-channel blocker administered intranasally affecting the atrioventricular node within minutes.
Methods: Reduction of Ventricular Rate in Patients with Atrial Fibrillation evaluated the efficacy and safety of etripamil for the reduction of ventricular rate (VR) in patients presenting urgently with AF-RVR (VR ≥110 beats per minute [bpm]), was randomized, double-blind, placebo-controlled, and conducted in Canada and the Netherlands.
Podcast on Self-administered Intranasal Etripamil for Symptomatic Paroxysmal Supraventricular Tachycardia: The RAPID Trial.
Cardiol Ther
December 2023
Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Article Synopsis
- Etripamil is a new self-administered intranasal medication being studied to treat PSVT, and its effectiveness was tested in the RAPID trial, which involved adults with documented PSVT episodes.
- Results showed that etripamil successfully converted PSVT to normal rhythm in 64.3% of patients within 30 minutes, significantly better than the 31.2% conversion rate with placebo, with mostly mild side effects reported.
Background Self-administration of investigational intranasal L-type calcium channel blocker etripamil during paroxysmal supraventricular tachycardia (PSVT) appeared safe and well-tolerated in the phase 3 NODE-301 (Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia) trial of adults with sustained atrioventricular nodal-dependent PSVT. The NODE-302 open-label extension further characterized etripamil safety and efficacy. Methods and Results Eligible patients were monitored via self-applied cardiac monitoring system for 5 hours after etripamil self-administration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!